{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:10:41Z","timestamp":1790251841905,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70117128"],"award-info":[{"award-number":["70117128"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03116-9","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:48:45Z","timestamp":1787143725000},"page":"2129-2132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Next-generation synthetic trials in hematology with generative artificial intelligence"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3649-2823","authenticated-orcid":false,"given":"Jan-Niklas","family":"Eckardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5916-3029","authenticated-orcid":false,"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"3116_CR1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/d41573-021-00190-9","volume":"21","author":"DG Brown","year":"2022","unstructured":"Brown DG, Wobst HJ, Kapoor A, Kenna LA, Southall NT. Clinical development times for innovative drugs. Nat Rev Drug Discov. 2022;21:793\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"3116_CR2","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/d41573-023-00132-7","volume":"22","author":"A Mullard","year":"2023","unstructured":"Mullard A. The high and redundant cost of failure in cancer drug development. Nat Rev Drug Discov. 2023;22:688\u2013688.","journal-title":"Nat Rev Drug Discov"},{"key":"3116_CR3","doi-asserted-by":"publisher","first-page":"e2415445","DOI":"10.1001\/jamanetworkopen.2024.15445","volume":"7","author":"A Sertkaya","year":"2024","unstructured":"Sertkaya A, Beleche T, Jessup A, Sommers BD. Costs of drug development and research and development intensity in the US, 2000-2018. JAMA Netw Open. 2024;7:e2415445.","journal-title":"JAMA Netw Open"},{"key":"3116_CR4","doi-asserted-by":"publisher","first-page":"e2453275","DOI":"10.1001\/jamanetworkopen.2024.53275","volume":"8","author":"A Mulcahy","year":"2025","unstructured":"Mulcahy A, Rennane S, Schwam D, Dickerson R, Baker L, Shetty K. Use of clinical trial characteristics to estimate costs of new drug development. JAMA Netw Open. 2025;8:e2453275.","journal-title":"JAMA Netw Open"},{"key":"3116_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jclinepi.2016.07.016","volume":"80","author":"M Briel","year":"2016","unstructured":"Briel M, Olu KK, von Elm E, Kasenda B, Alturki R, Agarwal A, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol. 2016;80:8\u201315.","journal-title":"J Clin Epidemiol"},{"key":"3116_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41375-026-02864-y","volume":"40","author":"J Chen","year":"2026","unstructured":"Chen J, Gale RP. Physician-complementing artificial intelligence in haematology: ushering in a new era. Leukemia. 2026;40:465\u20137.","journal-title":"Leukemia"},{"key":"3116_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41746-025-01563-9","volume":"8","author":"J-N Eckardt","year":"2025","unstructured":"Eckardt J-N, Srivastava I, Wang Z, Winter S, Schmittmann T, Riechert S, et al. Synthetic bone marrow images augment real samples in developing acute myeloid leukemia microscopy classification models. npj Digit Med. 2025;8:173.","journal-title":"npj Digit Med"},{"key":"3116_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41746-024-01076-x","volume":"7","author":"J-N Eckardt","year":"2024","unstructured":"Eckardt J-N, Hahn W, R\u00f6llig C, Stasik S, Platzbecker U, M\u00fcller-Tidow C, et al. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence. npj Digit Med. 2024;7:1\u201311.","journal-title":"npj Digit Med"},{"key":"3116_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S1470-2045(15)00362-9","volume":"16","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Serve H, H\u00fcttmann A, Noppeney R, M\u00fcller-Tidow C, Krug U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691\u20139.","journal-title":"Lancet Oncol"},{"key":"3116_CR10","doi-asserted-by":"publisher","unstructured":"Reddy KK, Hahn W, Winter S, Roellig C, Mueller-Tidow C, Serve H, et al. In silico trial simulation with artificial intelligence-generated synthetic control cohorts reproduces results of a randomized controlled trial. Acute Myeloid Leukemia. Preprint at https:\/\/doi.org\/10.64898\/2026.07.15.26358123 2026.","DOI":"10.64898\/2026.07.15.26358123"},{"key":"3116_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/jha2.873","volume":"5","author":"A Piciocchi","year":"2024","unstructured":"Piciocchi A, Cipriani M, Messina M, Marconi G, Arena V, Soddu S, et al. Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients. EJHaem. 2024;5:353\u20139.","journal-title":"EJHaem"},{"key":"3116_CR12","first-page":"e2300021","volume":"7","author":"S D\u2019Amico","year":"2023","unstructured":"D\u2019Amico S, Dall\u2019Olio D, Sala C, Dall\u2019Olio L, Sauta E, Zampini M, et al. Synthetic data generation by artificial intelligence to accelerate research and precision medicine in hematology. JCO Clin Cancer Inf. 2023;7:e2300021.","journal-title":"JCO Clin Cancer Inf"},{"key":"3116_CR13","doi-asserted-by":"publisher","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","volume":"1","author":"E Bernard","year":"2022","unstructured":"Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1:EVIDoa2200008.","journal-title":"NEJM Evid"},{"key":"3116_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2024.101536","volume":"37","author":"F Passamonti","year":"2024","unstructured":"Passamonti F, Corrao G, Castellani G, Mora B, Maggioni G, Della Porta MG, et al. Using real-world evidence in haematology. Best Pr Res Clin Haematol. 2024;37:101536.","journal-title":"Best Pr Res Clin Haematol"},{"key":"3116_CR15","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/s41375-025-02751-y","volume":"39","author":"RP Gale","year":"2025","unstructured":"Gale RP, Hochhaus A. Are real- world data real-world data? Leukemia. 2025;39:2311\u20132.","journal-title":"Leukemia"},{"key":"3116_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100914","volume":"54","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Corrao G, Castellani G, Mora B, Maggioni G, Gale RP, et al. The future of research in hematology: integration of conventional studies with real-world data and artificial intelligence. Blood Rev. 2022;54:100914.","journal-title":"Blood Rev"},{"key":"3116_CR17","doi-asserted-by":"publisher","first-page":"235:1","DOI":"10.1145\/3523273","volume":"54","author":"H Hu","year":"2022","unstructured":"Hu H, Salcic Z, Sun L, Dobbie G, Yu PS, Zhang X. Membership inference attacks on machine learning: a survey. ACM Comput Surv. 2022;54:235:1\u2013235:37.","journal-title":"ACM Comput Surv"},{"key":"3116_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s10462-025-11248-0","volume":"58","author":"W Yang","year":"2025","unstructured":"Yang W, Wang S, Wu D, Cai T, Zhu Y, Wei S, et al. Deep learning model inversion attacks and defenses: a comprehensive survey. Artif Intell Rev. 2025;58:242.","journal-title":"Artif Intell Rev"},{"key":"3116_CR19","unstructured":"Dwork, C. Differential Privacy. In: Bugliesi M, Preneel B, Sassone V, Wegener I (eds). Automata, Languages and Programming. Springer: Berlin, Heidelberg, 2006, pp 1\u201312."},{"key":"3116_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2025.101320","volume":"6","author":"L Pilgram","year":"2025","unstructured":"Pilgram L, Dankar FK, Drechsler J, Elliot M, Domingo-Ferrer J, Francis P, et al. A consensus privacy metrics framework for synthetic data. Patterns. 2025;6:101320.","journal-title":"Patterns"},{"key":"3116_CR21","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1038\/s41591-023-02578-z","volume":"29","author":"C Serrano","year":"2023","unstructured":"Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay J-Y, et al. Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors. Nat Med. 2023;29:2689\u201392.","journal-title":"Nat Med"},{"key":"3116_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7447","volume":"13","author":"E Farah","year":"2024","unstructured":"Farah E, Kenney M, Warkentin MT, Cheung WY, Brenner DR. Examining external control arms in oncology: A scoping review of applications to date. Cancer Med. 2024;13:e7447.","journal-title":"Cancer Med"},{"key":"3116_CR23","unstructured":"Food and Drug Administration. Good Machine Learning Practice for Medical Device Development: Guiding Principles. FDA 2025. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/good-machine-learning-practice-medical-device-development-guiding-principles (accessed 5 Feb2025)."},{"key":"3116_CR24","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/s44222-024-00245-7","volume":"2","author":"B van Breugel","year":"2024","unstructured":"van Breugel B, Liu T, Oglic D, van der Schaar M. Synthetic data in biomedicine via generative artificial intelligence. Nat Rev Bioeng. 2024;2:991\u20131004.","journal-title":"Nat Rev Bioeng"},{"key":"3116_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41568-026-00912-4","volume":"26","author":"J-N Eckardt","year":"2026","unstructured":"Eckardt J-N, Hahn W, Prelaj A, Bornh\u00e4user M, Middeke JM, Kather JN. Artificial intelligence-generated synthetic data for cancer research and clinical trials. Nat Rev Cancer. 2026;26:351\u201363.","journal-title":"Nat Rev Cancer"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03116-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03116-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03116-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:35Z","timestamp":1790250215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03116-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3116"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03116-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"17 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J-NE declares consulting services for AstraZeneca, Novartis, and Johnson & Johnson, holds shares in Cancilico, has received an institutional research grant from Novartis, and has received honoraria from Amgen, Astellas, AstraZeneca, Johnson & Johnson, Novartis, Pfizer, and Servier. MB has received lecture honoraria from Jazz Pharmaceuticals and MSD and has served on advisory boards for ActiTrexx and Jazz. JMM declares consulting services for Johnson & Johnson, Roche, Gilead, AbbVie, Jazz, Pfizer, Astellas, Novartis, AstraZeneca, Clycostem, holds shares in Cancilico and Synagen, has received institutional research grants from Johnson & Johnson, Jazz and Novartis; and has received honoraria from Novartis, Roche, Johnson & Johnson, AbbVie, Pfizer, Sanofi, Astellas and Beigene.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}